Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179477 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Peter Hillmen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Apellis Pharmaceuticals, Inc., Waltham, MA 02451, USA. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Complement Inactivating Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Apellis Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB.
Abstract (Originalsprache)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and potentially life-threatening hematologic disorder caused by a somatic mutation in a relevant portion of hematopoietic stem cells. Mutation of the phosphatidylinositol glycan biosynthesis class A (PIGA) gene prevents the expression of cell-surface proteins, including the complement regulatory proteins CD55 and CD59. With decreased or a lack of CD55 and CD59 expression on their membranes, PNH red blood cells become susceptible to complement-mediated hemolysis (symptoms of which include anemia, dysphagia, abdominal pain, and fatigue), leading to thrombosis. State-of-the-art PNH treatments act by inhibiting the dysregulated complement at distinct points in the activation pathway: late at the C5 level (C5 inhibitors, eculizumab, ravulizumab, and crovalimab), centrally at the C3 level (C3/C3b inhibitors and pegcetacoplan), and early at the initiation and amplification of the alternative pathway (factor B inhibitor, iptacopan; factor D inhibitor, danicopan). Through their differing mechanisms of action, these treatments elicit varying profiles of disease control and offer valuable insights into the molecular underpinnings of PNH. This narrative review provides an overview of the mechanisms of action of the six complement inhibitors currently approved for PNH, with a focus on the C3/C3b-targeted therapy, pegcetacoplan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Apellis Pharmaceuticals, Inc., Waltham, MA 02451, USA.
- Swedish Orphan Biovitrum AB, 171 65 Stockholm, Sweden.
ORCID-Profile: Martin Kolev
Förderung
- Apellis Pharmaceuticals, Inc.
- Swedish Orphan Biovitrum AB
Zitieren
APA
Hillmen, P., Horneff, R., Yeh, M., Kolev, M., & Deschatelets, P. (2024). Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179477
Vancouver
Hillmen P, Horneff R, Yeh M, Kolev M, Deschatelets P. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179477
BibTeX
@article{Hillmen2024,
author = {Hillmen, Peter and Horneff, Regina and Yeh, Michael and Kolev, Martin and Deschatelets, Pascal},
title = {Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179477}
}
EUVIMED